Literature DB >> 8258344

Chemical reactivity of an HLA-B27 thiol group.

M A Whelan1, J R Archer.   

Abstract

Techniques have been developed to measure the reactivity of free thiols in the HLA class I antigen-binding cleft. HLA-B27, which sequencing predicts has a free cysteine at position 67, reacts rapidly with the positively charged thiol reagent monobromotrimethyl-ammoniobimane bromide (qBBr) to give products which are identifiable by isoelectric focusing. HLA-B38, B39, B64 and B65, all of which have a similar Cys 67, react less strongly. Several other class I molecules, notably HLA-C antigens, are reactive in this system, and it may be capable of recognizing subtypes such as A*0207 which also carry free cysteine. The accessibility of thiol to qBBr depends both on the chemistry of the class I molecule and other factors in the cell. Two human cell lines which are known to carry identical B27 genes but do not present the same peptides, differ considerably in the accessibility of their B27 thiol. Evidence from mouse cells transfected with mutant B27 genes suggests that a unique lysine at position 70 in the wild-type molecule increases reactivity to thiol-reactive metabolites. The failure of B27 to give a complete reaction with qBBr in our model systems suggests that it can exist in more than one chemical form. This may leave the molecule susceptible to oxidation, causing errors in T cell recognition and an exaggerated inflammatory response.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8258344     DOI: 10.1002/eji.1830231233

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  7 in total

Review 1.  Ankylosing spondylitis, IgA, and transforming growth factors.

Authors:  J R Archer
Journal:  Ann Rheum Dis       Date:  1995-07       Impact factor: 19.103

2.  Yersinia enterocolitica serotype O:3 alters the expression of serologic HLA-B27 epitopes on human monocytes.

Authors:  M Wuorela; S Jalkanen; J Kirveskari; P Laitio; K Granfors
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

Review 3.  From HLA-B27 to spondyloarthritis: a journey through the ER.

Authors:  Robert A Colbert; Monica L DeLay; Erin I Klenk; Gerlinde Layh-Schmitt
Journal:  Immunol Rev       Date:  2010-01       Impact factor: 12.988

4.  Alteration of HLA-B27 peptide presentation after infection of transfected murine L cells by Shigella flexneri.

Authors:  F Boisgérault; J Mounier; V Tieng; M C Stolzenberg; I Khalil-Daher; M Schmid; P Sansonetti; D Charron; A Toubert
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

Review 5.  HLA-B27 misfolding and spondyloarthropathies.

Authors:  Robert A Colbert; Monica L DeLay; Gerlinde Layh-Schmitt; Dawn P Sowders
Journal:  Prion       Date:  2009-01-03       Impact factor: 3.931

6.  Pathogenicity of Misfolded and Dimeric HLA-B27 Molecules.

Authors:  Antony N Antoniou; Izabela Lenart; David B Guiliano
Journal:  Int J Rheumatol       Date:  2011-03-30

Review 7.  Aetiology and pathogenesis of reactive arthritis: role of non-antigen-presenting effects of HLA-B27.

Authors:  Sanna Vähämiko; Markus A Penttinen; Kaisa Granfors
Journal:  Arthritis Res Ther       Date:  2005-05-26       Impact factor: 5.156

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.